NRG-GU014

Open to Accrual

Return to Protocol Table

Randomized Phase II Trial Of Pembrolizumab and Radiation vs. Radiation And Concurrent Chemotherapy For High-Grade T1 Bladder Cancer (PARRC Trial)

Principal Investigator

Brian Baumann, MD,

Co-Principal Investigator(s)

Scott Delacroix, MD,

Status

Open to Accrual

Date Opened To Accrual

March 07 2025

Disease Site

Genitourinary [GU]

Bladder

Phase

Developmental Therapeutics

Yes

Primary Objective

To compare bladder-intact event-free survival.

Patient Population

Pathologically (histologically) proven diagnosis of T1 high-grade non-muscle invasive urothelial carcinoma of the bladderwithout radiographic evidence of regional nodal disease or metastatic disease.

Target Accrual

160

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.